This video highlights the benefits of electronic prescribing of controlled substances (EPCS) and provides an overview of the DEA regulatory requirements for EPCS.
Methodist Health System (Omaha, Neb.) leverages fingerprint biometric authentication from Imprivata to enable e-Prescribing of controlled substances to improve patient satisfaction, eliminate dual-prescribing workflows and address drug diversion.
Lexington, Mass. — December 18, 2014— Imprivata® (NYSE: IMPR) today announced that members of management will participate in the 33rd Annual J.P. Morgan Healthcare Conference.
Omar Hussain, President and CEO, and Jeff Kalowski, Chief Financial Officer, will present at the conference in San Francisco, California on Wednesday, January 14th at 3:30 PM PST.
An audio webcast of the presentation will be available live and archived on Imprivata’s investor relations website at http://investor.imprivata.com